[PDF] Top 20 THROMBOCYTOSIS AS PROGNOSTIC FACTOR FOR SURVIVAL IN PATIENTS WITH ADVANCED NON SMALL CELL LUNG CANCER TREATED WITH FIRST- LINE CHEMOTHERAPY.

... of thrombocytosis did not differ sig- nificantly between ages, sex and ...contrary, in the present study we identified significant association between elevated platelet counts and advanced stage, ... See full document

... like patients with an EGFR activation mutation, impressive im- provements in the treatment of lung cancer patients were achieved ...for patients with ... See full document

... to chemotherapy with a PFS of 2.2 months in overall population, and a PFS around ...months in Asian population.[7–9] The phase 4 Tarceva Lung Cancer Survival Treatment ... See full document

... finding in cancer patients. Up to 30% of patients with different types of tumors have been reported to suffer from anemia ...is chemotherapy or radiotherapy. The factors ... See full document

... increase in the incidence of lung cancer in women in re- cent years, it has brought broad concerns with its unique clinical and epidemiological characteristics and beter ...women ... See full document

... In survival analyses, we observed the polymorphism rs2736109 significantly associated with PFS of advanced NSCLC patients receiving first-line platinum-based ...apparent ... See full document

... on Non-Small Cell Lung Cancer (NSCLC) are scarce with regard to the private health care in ...the survival of patients with NSCLC in a ... See full document

... for patients with non- small cell lung cancer after the failure of platinum- containing ...second- line chemotherapy in pretreated patient with ... See full document

... early-stage non-small-cell lung cancer (NSCLC) is considered a potentially curable disease following complete resection, patients have a wide spectrum of survival ... See full document

... 276 advanced NSCLC patients were included, with 11 ...fifteen patients received first-line platinum-based doublet, with gemcitabine in 63 ...docetaxel in 18 ... See full document

... of non-small-cell lung cancer patients exposed to erlotinib in any line of ...of non- small-cell lung cancer patients from ... See full document

... limitations. First, tumor programmed death-ligand 1 expression, which can provide direct information about the degree of immune paralysis in tumor microenvironment, was not ...immune cell ... See full document

... Lung cancer leads all other cancers in both incidence and mortality ...worldwide. Non-small cell lung cancer (NSCLC) accounts for 89% of all lung ... See full document

... the first type of immune cell that responds to the site of infection and attack invaders ...found in tumors are more likely to contribute to tumor growth, progression, and immunosuppression than they ... See full document

... significant factor (regression coefficient of ...listed in Table 3. Additionally, a longer SPP time was associated with several clinical Figure ...trends in survival data. A. Trend ... See full document

... compared non-platinum single-agent therapy versus non-platinum combination therapy, or non-platinum therapy versus platinum combination therapy in pa- tients over 70 years of age with ... See full document

... Objective: Lung cancer is a global public health problem and is associated with high ...mortality. Lung cancer could be largely avoided by reducing the prevalence of ...the ... See full document

... Metastatic lung cancer is the type of lung cancer in which cancer cells from any part or any other organ of the body spreads through towards the ...firstly cancer began is ... See full document

... presented with hemoptysis for two ...working in a restaurant in Japan for 5 years and reported having ingested a large number of raw peanuts just before the hemoptysis ...haziness in the right ... See full document

... radiography with or without chest ...procedure. In all patients, visual inspection of the larynx, vocal cords, trachea, carina, and all segmental orifices of both lungs was ...bronchoscope, ... See full document